Erickson Steven K, Schwarzkopf Steven B, Palumbo Donna, Badgley-Fleeman Jennifer, Smirnow Alexis M, Light Gregory A
University of Rochester Medical Center, Department of Psychiatry, New York 14642, USA.
Clin Neuropharmacol. 2005 Jul-Aug;28(4):179-84. doi: 10.1097/01.wnf.0000173714.61744.e6.
There have been many advancements in the pharmacologic treatment of schizophrenia; however, negative symptoms and cognitive impairment remain an intractable part of this illness. Donepezil is an anticholinesterase inhibitor with cognitive enhancing effects approved for the treatment of Alzheimer disease that has shown some benefit in the treatment of schizophrenia. In this study, 15 inpatients at a state hospital with a history of schizophrenia were administered donepezil in a randomized, double-blind, crossover design. Neurocognitive testing and psychiatric ratings were completed at baseline and at regular intervals for 18 weeks. Results indicated that donepezil treatment was associated with modest improvements in psychiatric symptoms and improved verbal learning. These results suggest that donepezil may be helpful as adjunctive therapy for the treatment of psychiatric symptoms and cognitive impairment in a subgroup of schizophrenic patients.
在精神分裂症的药物治疗方面已经取得了许多进展；然而，阴性症状和认知障碍仍然是这种疾病难以解决的部分。多奈哌齐是一种具有认知增强作用的抗胆碱酯酶抑制剂，已被批准用于治疗阿尔茨海默病，在精神分裂症治疗中也显示出一定益处。在本研究中，对一家州立医院的15名有精神分裂症病史的住院患者采用随机、双盲、交叉设计给予多奈哌齐治疗。在基线时以及之后18周的定期时间点完成神经认知测试和精神科评定。结果表明，多奈哌齐治疗与精神症状的适度改善以及言语学习能力的提高相关。这些结果表明，多奈哌齐可能有助于作为辅助治疗手段，用于治疗一部分精神分裂症患者的精神症状和认知障碍。
